Powered by GlobalData

COVID-19 Global Trials Tracker

The Coronavirus Company/Trials Tracker lists clinical trials in all stages of clinical development (from Phase 0 to Phase IV) for COVID-19 indication. This list is updated dynamically based on the GloblaData Pharma Intelligence Center Clinical Trials database.

The Sponsor company is responsible for implementation, data analysis and providing funds for the clinical study.

To view all pipeline pharmaceuticals for COVID-19 indication including preclinical and preregistration, visit the Coronavirus Drugs Tracker.

Trial Title Sponsor Drug Name Trial Phase Trial Status
Community-Acquired Pneumonia : Evaluation of Corticosteroids (CAPE_COD) University Hospital Tours; CHRU de Tours hydrocortisone Phase III Ongoing, recruiting
Lessening Organ Dysfunction with Vitamin C (LOVIT) University of Sherbrooke; Centre de recherche du CHUS; Apollo Hospitals Educational and Research Foundation ascorbic acid Phase III Ongoing, recruiting
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study Ansun Biopharma Inc DAS-181 Phase III Ongoing, recruiting
Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19) Chengdu University of Traditional Chinese Medicine Hospital undisclosed traditional Chinese medicine Phase III Ongoing, recruiting
Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 (DC-COVID-19) Shanghai Public Health Clinical Center cobicistat; darunavir Phase III Completed
MR-Evaluation of Renal Function in Septic Patients (MERSEP) Uppsala University ringer's acetate Phase II Ongoing, recruiting
Phase IIb Field Study of PrEP-001 PrEP Biopharm Ltd PrEP-001 Phase II Planned
Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections Nitric Solutions Inc nitric oxide Phase II Ongoing, recruiting
Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients with ARDS (CHILL-pilot) University of Maryland Baltimore Phase II Ongoing, recruiting
Efficacy and Safety Study of HLCM051 (MultiStem) for Pneumonic Acute Respiratory Distress Syndrome (ONE-BRIDGE) HEALIOS KK Multistem Phase II Ongoing, recruiting
Phase I Study of BPI-002 BeyondSpring Inc BPI-002 Phase I Planned
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) Millennium Pharmaceuticals Inc TAK-981 Phase I Ongoing, recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 BioCryst Pharmaceuticals Inc galidesivir Phase I Ongoing, recruiting
Sad and Mad Study with Iv and Sc Doses of ARGX-117 (ARGX-117) Argenx SE ARGX-117; efgartigimod alfa Phase I Ongoing, recruiting
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers Inovio Pharmaceuticals Inc INO-4800 Phase I Ongoing, not recruiting
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- acquired Pneumonia (REMAP-CAP) University Medical Center Utrecht (amoxicillin sodium + clavulanate potassium); (lopinavir + ritonavir); (piperacillin sodium + tazobactam sodium); anakinra; ascorbic acid; azithromycin; cefotaxime sodium; ceftaroline fosamil; ceftriaxone sodium; clarithromycin; convalescent plasma; Cortef; erythromycin; interferon beta-1a; levofloxacin; low molecular weight heparin; moxifloxacin; oseltamivir phosphate; propagermanium; roxithromycin; sarilumab; simvastatin; tocilizumab; unfractionated heparin Phase IV Ongoing, recruiting
A Prospective Comparative Study for Xue-Bi-Jing Injection in the Treatment of Novel Coronavirus Pneumonia (COVID-19) Guangzhou Medical University Hospital One; Guangzhou Institute of Respiratory Diseases Xuebijing Phase IV Completed
A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV) Central South University Xiangya Hospital umifenovir Phase IV Planned
A randomized, Open-label, Blank-controlled Trial for Lian-Hua Qing-Wen Capsule/Granule in the Treatment of Suspected Novel Coronavirus Pneumonia (COVID-19) Hebei Yiling Hospital; Renmin Hospital of Wuhan University Hubei General Hospital Lianhua Qingwen Phase IV Completed
A Single Arm Study of Combination of Traditional Chinese and Western Medicine in the Treatment of Novel Coronavirus Pneumonia (COVID-19) Hubei Integrated Traditional Chinese and Western Medicine Hospital undisclosed traditional Chinese medicine; western medicine Phase IV Planned
Note: for more detailed information please visit the GloblaData Pharma Intelligence Center.
×

To sign up for a free, non-obligatory demo and find out how GlobalData can help your business decode the future – Click here.

If you are a subscriber to the GlobalData Pharma Intelligence Center - Click here to log in